secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-126288
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium Q3 revenue $12.2M, net loss near zero; retains itolizumab rights after Ono termination
--------------------------------------------------------------------------------

- Q3 revenue $12.2M (up 37% YoY) from Ono partnership; net loss ~$7,000 vs $3.7M loss in Q3 2023.
- Cash $25.9M; sufficient into Q4 2025 assuming accelerated EQUATOR study, pausing EQ101/EQ302, and cost reductions.
- Ono partnership ended after substantial non-dilutive funding; Equillium retains full rights to itolizumab.
- Phase 3 EQUATOR aGVHD study enrollment paused; potential topline acceleration to Q1 2025.
- Partner Biocon completed Phase 2 ulcerative colitis study; topline data expected Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/0000950170-24-126288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/eq-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer